

## Anti-CD19 [FMC63] Bulk Size Ab00613-10.0-BT

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Human IgG1, Kappa

**Clone Number:** FMC63

**Alternative Name(s) of Target:** B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19; Leu12; T-cell surface antigen Leu-12

**UniProt Accession Number of Target Protein:** P15391

**Published Application(s):** Depletion, FACS, in vivo, IP, FC, IF, IHC

**Published Species Reactivity:** Human

**Immunogen:** Human prolymphocytic leukaemia cell line JVM3.

**Specificity:** This antibody is specific for human CD19, a 95 kDa protein expressed in the B-lymphocyte lineage.

**Application Notes:** FMC63 was used for four years as a CD19 antibody in various labs prior to its original publication. There, it was reported that the antibody precipitates CD19 and inhibits the binding of other CD19 antibodies to it (Zola et al., 1991; PMID: 1725979). FMC63 was used for IF and FACS of peripheral blood mononuclear cells (PBMC) from patients with multiple myeloma (MM) (Szczepek et al., 1997; PMID: 9057669) and receptor for hyaluronan (HA)-mediated motility (RHAMM) expressing malignant B-lineage cells in myeloma (Crainie et al., 1999; PMID: 10029598). FMC63 was used for IHC and IIP of B cells in lymphocyte-filled villi and IIP of jejunal isolated lymphoid follicle, respectively, in small bowel specimens from human patients (Moghaddami et al., 1998; PMID: 9834269). FNC63 was used to induce B cell depletion in vivo (DiLillo et al., 2011; PMID: 21248259). FMC63 has been incorporated into a CD19 scFv-41BB- CD3 $\zeta$  fusion protein-encoding lentiviral vector, which was used in combination with a UCART19 cell therapy to cure high-risk CD19+ infant acute lymphoblastic leukemia (Qasim et al., 2017). This clone did not compete with clone HD37 (available as Ab00214) (Sakemura et al., 2023; PMID: 37879074).

**Antibody First Published in:** Zola et al. Preparation and characterization of a chimeric CD19 monoclonal antibody Immunol Cell Biol. 1991 Dec;69 ( Pt 6):411-22. doi: 10.1038/icb.1991.58 PMID:1725979

**Note on publication:** The original publication discusses the production of FMC63, a mouse-human chimera of the CD19 cluster monoclonal antibody.

## Product Form

**Size:** 1 mg Purified antibody in bulk size.

**Purification:** Protein A affinity purified

**Supplied In:** PBS only.

**Storage Recommendation:** Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.